Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

New, improved formulation set to replace EGRIFTA SV®MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or ...

The new formula will replace EGRIFTA SV and treat excess visceral abdominal fat in adults with HIV and Lipodystrophy.

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

Theratechnologies (THTX) announced that the FDA has approved the Company’s supplemental Biologics License Application, or sBLA, for the F8 ...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Dr. Georgeanne Botek, DPM, is a podiatrist who has been part of the Cleveland Clinic’s Department of Orthopaedic Surgery ...

This is of particular concern since peripheral edema was one of the several criteria employed to reach the diagnosis of CHF. Peripheral edema is a not too uncommon finding with direct vasodilators ...

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...